Rezolute (NASDAQ:RZLT) Coverage Initiated by Analysts at Lake Street Capital

Lake Street Capital initiated coverage on shares of Rezolute (NASDAQ:RZLT) in a research note issued to investors on Wednesday, MarketBeat Ratings reports. The brokerage set a “buy” rating and a $9.00 price target on the stock. Lake Street Capital’s price objective points to a potential upside of 120.05% from the company’s previous close.

Several other research firms also recently weighed in on RZLT. HSBC raised shares of Rezolute to a “buy” rating in a research note on Friday. Guggenheim lifted their price objective on Rezolute from $6.00 to $11.00 and gave the stock a “buy” rating in a report on Monday, June 15th. Maxim Group boosted their target price on Rezolute from $10.00 to $14.00 and gave the company a “buy” rating in a research note on Tuesday, June 2nd. Wall Street Zen lowered Rezolute from a “hold” rating to a “sell” rating in a research report on Tuesday, June 30th. Finally, HC Wainwright lifted their price target on Rezolute from $5.00 to $10.00 and gave the stock a “buy” rating in a research note on Friday, September 25th. Eleven equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $10.44.

Rezolute Price Performance

Shares of NASDAQ RZLT opened at $4.09 on Wednesday. Rezolute has a one year low of $1.07 and a one year high of $11.46. The firm’s 50 day simple moving average is $4.55 and its two-hundred day simple moving average is $4.04. The stock has a market capitalization of $395.59 million, a P/E ratio of -5.38 and a beta of 0.60.

Rezolute (NASDAQ:RZLT) last announced its quarterly earnings data on Thursday, September 24th. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.05). As a group, equities analysts expect that Rezolute will post -0.6 earnings per share for the current fiscal year.

Institutional Trading of Rezolute

Several large investors have recently added to or reduced their stakes in the stock. Sequoia Financial Advisors LLC bought a new stake in Rezolute during the 2nd quarter valued at approximately $75,000. WINTON GROUP Ltd bought a new position in shares of Rezolute in the 2nd quarter worth approximately $88,000. Integrated Wealth Concepts LLC purchased a new position in shares of Rezolute in the 2nd quarter valued at approximately $143,000. Wellington Management Group LLP purchased a new position in shares of Rezolute in the 2nd quarter valued at approximately $276,000. Finally, Public Employees Retirement System of Ohio bought a new stake in shares of Rezolute during the second quarter valued at approximately $267,000. Institutional investors own 82.97% of the company’s stock.

Rezolute News Summary

Here are the key news stories impacting Rezolute this week:

• Positive Sentiment: Craig-Hallum upgraded Rezolute from “Hold” to “Buy” and raised its price target to $7 from $4, signaling increased confidence in the company’s outlook. Craig-Hallum upgrades Rezolute to Buy from Hold
• Positive Sentiment: HC Wainwright maintained its “Buy” rating and $10 price target while projecting a significant improvement in profitability over the long term. Its estimates rise to $1.42 in EPS for fiscal 2030 and $2.94 for fiscal 2031, compared with continued losses in the nearer-term years. Rezolute Stock Earnings Estimates Decreased by HC Wainwright
• Neutral Sentiment: The unchanged $10 HC Wainwright target provides a more optimistic valuation framework than the current share price, but the estimates depend on Rezolute reaching profitability later in the decade. The company remains unprofitable, with analysts expecting a loss for the current fiscal year.
• Negative Sentiment: HC Wainwright reduced several near- and medium-term EPS forecasts: fiscal 2027 EPS was lowered to $(0.57) from $(0.45), Q1 2027 to $(0.16) from $(0.12), Q2 2027 to $(0.14) from $(0.10), and Q4 2027 to $(0.13) from $(0.09). Fiscal 2028 was also trimmed slightly to $(0.34) from $(0.33), suggesting higher anticipated losses before a projected turnaround.

About Rezolute

Rezolute, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for rare and metabolic diseases. The company’s research is centered on therapies that address abnormal insulin activity and other conditions involving disrupted glucose regulation.

Rezolute’s leading product candidate is RZ358, an investigational monoclonal antibody designed to reduce the effects of excessive insulin. The therapy is being developed primarily for congenital hyperinsulinism, a rare disorder in which the pancreas produces too much insulin and causes potentially severe, recurrent hypoglycemia.